Skip to main content

Table 4 Linear mixed models of trouble swallowing, dry mouth, and numbness/tingling

From: Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States

 Trouble swallowingaDry mouthbNumbness/tinglingc
EffectEstimate (SE)P-valueEstimate (SE)P-valueEstimate (SE)P-value
Intercept5.03 (2.519)0.0472.81 (2.388)0.2423.94 (1.791)0.029
Time (months) since diagnosis−0.05 (0.014)0.0010.04 (0.011)0.00030.02 (0.010)0.070
Treatment: cetuximab±RT (vs. cisplatin±RT)−0.11 (0.546)0.8350.17 (0.494)0.736−0.15 (0.367)0.677
Treatment* time since diagnosis0.01 (0.050)0.842−0.02 (0.038)0.6050.01 (0.035)0.820
Age at diagnosis−0.04 (0.022)0.070−0.01 (0.021)0.556−0.06 (0.016)< 0.0001
Male (vs. female)−0.81 (0.417)0.053−0.72 (0.399)0.071−0.49 (0.300)0.100
White (vs. minority/unknown)0.26 (0.378)0.5000.44 (0.362)0.229−0.05 (0.272)0.861
Impaired composite performance status (vs. not impaired)0.97 (0.748)0.197−0.11 (0.716)0.8790.49 (0.537)0.359
Weighted index of comorbid conditions0.22 (0.199)0.2690.11 (0.190)0.5570.16 (0.143)0.264
Smoking status: current or past (vs. never/unknown/undocumented)− 0.32 (0.472)0.4940.19 (0.451)0.6770.41 (0.339)0.227
Alcohol status0.2920.0740.683
 Current or past abuse (vs. never/unknown/undocumented)0.44 (0.494)0.377−0.32 (0.472)0.5040.31 (0.355)0.387
 Current or past use (vs. never/unknown/undocumented)−0.25 (0.404)0.540−0.85 (0.387)0.0280.17 (0.291)0.567
Stage at start: Stage III (vs. Stage IV)0.30 (0.358)0.399−0.15 (0.343)0.6660.05 (0.258)0.862
Oral (vs. non-oral)0.96 (0.966)0.3190.13 (0.917)0.889−0.63 (0.685)0.357
Pharynx (vs. non-pharynx)1.79 (0.942)0.0580.70 (0.894)0.434−0.82 (0.667)0.221
Larynx (vs. non-larynx)1.06 (0.994)0.285−0.07 (0.944)0.941−0.79 (0.704)0.261
HPV test results (positive vs. non-positive)0.61 (1.005)0.5411.52 (0.957)0.1120.46 (0.719)0.526
P16 test results (positive vs. non-positive)−0.24 (0.418)0.5640.38 (0.401)0.3440.60 (0.303)0.048
Feeding tube placement (vs. not placed)0.95 (0.360)0.0080.77 (0.345)0.026−0.12 (0.259)0.651
BMI−0.03 (0.029)0.3800.05 (0.028)0.1070.01 (0.021)0.618
Insurance0.1800.0830.026
 Only public (vs. only private)0.64 (0.484)0.1840.94 (0.462)0.0430.89 (0.347)0.011
 Both public and private (vs. only private)0.10 (0.454)0.836−0.004 (0.434)0.9930.87 (0.326)0.008
 Other/unknown/undocumented (vs. only private)2.04 (1.113)0.0671.50 (1.054)0.1710.36 (0.785)0.644
US Region South (vs. non-South)0.22 (1.693)0.897−0.44 (1.591)0.7830.79 (1.190)0.508
  1. Reference level for each comparison is in parentheses
  2. BMI body mass index, HPV human papilloma virus, RT radiation therapy, SE standard error, US United States
  3. aAnalysis is based on 237 patients and 1848 observations
  4. bAnalysis is based on 237 patients and 1857 observations
  5. cAnalysis is based on 237 patients and 1851 observations
  6. *refers to an interaction